Mark Altmeyer

Biography

Mark Altmeyer is the Chief Commercial Officer and President of Axovant Sciences GmbH and serves on the Board of Directors of Myovant Sciences Ltd. He has three decades of experience leading successful drug commercialization efforts as a pharmaceutical executive. He served as Chief Executive Officer and President of Otsuka America Pharmaceutical, Inc. from 2009-2014, leading 1,700 employees and growing total revenues from $2.6B to over $5B. At Otsuka America, he led the launch of ABILIFY®, the top-selling CNS drug in history and the number 1 selling drug in the United States in 2013. Prior to Otsuka, he held a number of executive leadership roles at Bristol-Myers Squibb, including Senior Vice President, Global Commercialization and Senior Vice President, Neuroscience Business Unit. He holds an M.B.A. from Harvard Business School and a B.A. from Middlebury College. Mark Altmeyer is the Chief Commercial Officer and President of Axovant Sciences GmbH and serves on the Board of Directors of Myovant Sciences Ltd. He has three decades of experience leading successful drug commercialization efforts as a pharmaceutical executive. He served as Chief Executive Officer and President of Otsuka America Pharmaceutical, Inc. from 2009-2014, leading 1,700 employees and growing total revenues from $2.6B to over $5B. At Otsuka America, he led the launch of ABILIFY®, the top-selling CNS drug in history and the number 1 selling drug in the United States in 2013. Prior to Otsuka, he held a number of executive leadership roles at Bristol-Myers Squibb, including Senior Vice President, Global Commercialization and Senior Vice President, Neuroscience Business Unit. He holds an M.B.A. from Harvard Business School and a B.A. from Middlebury College.

Research Interest

Pharmaceutical Analysis and Quality Assurance  Industrial Pharmacy Clinical Pharmacy  Pharmaceutical Administration Medicinal Chemistry  Drug Discovery and Development